---
id: ags-beers-alternatives-2025
title: "AGS Alternatives List for Potentially Inappropriate Medications in Older Adults"
short_title: "AGS Alternatives 2025"

organization: American Geriatrics Society
collaborators: null
country: US
url: https://www.americangeriatrics.org/practice-tools/quality-provider-tools-older-adults/ags-beers-criteria-potentially-inappropriate
doi: null
pmid: null
open_access: true

specialty: geriatrics
guideline_type: clinical-practice
evidence_system: AGS
conditions:
  - polypharmacy
  - medication safety in the elderly
tags:
  - beers criteria
  - prescribing safety
  - de-prescribing
  - pharmacogeriatrics
  - medication management

publication_date: 2025-05-10
previous_version_date: null
status: current
supersedes: null
superseded_by: null

pdf_path: null
has_pdf: false
last_reviewed: 2025-12-23
---

## Scope
New 2025 evidence-based clinical tool designed as a companion to the AGS Beers Criteria®, providing specific safer therapeutic alternatives (both pharmacologic and nonpharmacologic) for older adults.

## Key Recommendations

### Insomnia and Agitation
- **Avoid**: Benzodiazepines and "Z-drugs" (zolpidem, zaleplon, eszopiclone).
- **Alternatives**: 
  - **First-line**: Cognitive Behavioral Therapy for Insomnia (CBT-I) and sleep hygiene.
  - **Pharmacologic**: Melatonin, ramelteon, or low-dose trazodone (if depression is present). Doxepin (≤6 mg) can be considered.

### Pain Management
- **Avoid**: Chronic NSAIDs (due to GI, renal, and CV risk) and skeletal muscle relaxants.
- **Alternatives**: 
  - **First-line**: Physical therapy, gentle exercise, heat/cold therapy.
  - **Pharmacologic**: Acetaminophen (topical or oral), topical NSAIDs (diclofenac gel), or SNRI (e.g., duloxetine) for neuropathic or musculoskeletal pain.

### Depression
- **Avoid**: Tricyclic Antidepressants (TCAs) due to highly anticholinergic side effects and orthostasis.
- **Alternatives**: 
  - **First-line**: SSRIs (e.g., sertraline, escitalopram) or SNRIs.
  - **Safety**: Monitor for SIADH/hyponatremia when initiating SSRIs/SNRIs.

### Urinary Incontinence
- **Avoid**: Anticholinergic medications (e.g., oxybutynin, tolterodine) which increase the risk of cognitive decline and falls.
- **Alternatives**: 
  - **First-line**: Bladder training, pelvic floor muscle exercises.
  - **Pharmacologic**: Mirabegron (beta-3 agonist) or vaginal estrogen (for GSM-associated symptoms).

### Acid Reflux (GERD)
- **Avoid**: Long-term Proton Pump Inhibitors (PPIs) (>8 weeks) unless there is a high-risk indication (e.g., chronic NSAID use).
- **Alternatives**: 
  - **First-line**: Weight loss, head of bed elevation, avoiding trigger foods.
  - **Pharmacologic**: H2-receptor antagonists (e.g., famotidine) as a step-down or on-demand therapy.

### De-prescribing Framework
- **Review**: Conduct a regular medication review at every visit.
- **Taper**: When discontinuing long-term medications (e.g., PPIs, benzos), use a slow tapering schedule to avoid withdrawal symptoms or rebound effect.
